Drawing based on the description in the official product monograph. No photo yet.
“15 mg extended-release tablets are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with 'a15' on one side”
a15 pill
Pill with imprint a15 is purple, capsule, 8 mm and has been identified as Upadacitinib 15 mg. It is used for rheumatoid arthritis. It is supplied by Abbvie Corporation.
Sold in Canada
Upadacitinib 15 mg
- Brand
- Rinvoq
- Imprint
- a15
- Strength
- 15 mg
- Used for
- Rheumatoid arthritis
- Color
- Purple
- Shape
- Capsule / oblong
- Size
- 8 mm
- Form
- Tablet (extended-release)
- Manufacturer
- Abbvie Corporation
- Drug class
- Cancer medicine (kinase inhibitor)
- Sold in
- Canada
- DIN
- 02495155
Source: Health Canada's Drug Product Database and the official product monograph. Last checked .
Report a mistake
What is Upadacitinib used for?
Upadacitinib is used for rheumatoid arthritis.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
Rheumatoid Arthritis
RINVOQ® is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
Psoriatic Arthritis
RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
Atopic Dermatitis
RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
Ulcerative Colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for UC, or with potent immunosuppressants such as azathioprine and cyclosporine.
Crohn’s Disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for CD, or with potent immunosuppressants such as azathioprine and cyclosporine.
. 6 Ankylosing Spondylitis
RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
. 7 Non-radiographic Axial Spondyloarthritis
RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
Polyarticular Juvenile Idiopathic Arthritis
RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
Giant Cell Arteritis
RINVOQ is indicated for the treatment of adults with giant cell arteritis.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
From the FDA-approved label on DailyMed (published Jul 15, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- Your pill shows a15.
- It is purple, capsule, 8 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Sold in Canada as Rinvoq by Abbvie Corporation.
In Canada: prescription only.
Ingredients
Active: Upadacitinib
Other pills with imprint A 15
Same imprint, different listing. Check the color, size and maker against your pill.
- A15 Aripiprazole 15 mg Yellow, round, 7 mm Used for schizophrenia
- A15 Aripiprazole 15 mg White, rectangle, 10 mm Used for schizophrenia
- A 15 Binimetinib 15 mg Yellow, oval, 12 mm Used for melanoma
- A 15 Binimetinib 15 mg Yellow, oval Used for melanoma
- A 15 Diltiazem Hydrochloride 420 mg White, oval, 19 mm Used for high blood pressure and atrial fibrillation (irregular heartbeat)
- A15 Potassium Chloride 1125 mg White, capsule, 20 mm Used for low potassium
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
P171
Colchicine 0.6 mg
Purple, capsule, 8 mm
Used for gout and amyloidosis
-
A10
Colchicine 0.6 mg
Purple, capsule, 8 mm
Used for gout and amyloidosis
- C Colchicine 0.6 mg Purple, capsule, 8 mm Used for gout and amyloidosis
- CO6 Colchicine 0.6 mg Purple, capsule, 8 mm Used for gout and amyloidosis
- C6 Colchicine 0.6 mg Purple, capsule, 8 mm Used for gout and amyloidosis
- 175 GG 339 Levothyroxine Sodium 175 mcg Purple, capsule, 9 mm Used for goiter and myxedema
Other Upadacitinib pills
- a15 Upadacitinib 15 mg Purple, capsule, 14 mm Used for rheumatoid arthritis
- a30 Upadacitinib 30 mg Red, capsule, 14 mm Used for rheumatoid arthritis
- a30 Upadacitinib 30 mg Red, capsule, 8 mm Used for rheumatoid arthritis
- a45 Upadacitinib 45 mg Yellow, capsule, 14 mm Used for rheumatoid arthritis
- a45 Upadacitinib 45 mg Yellow, capsule, 8 mm Used for rheumatoid arthritis